Archive | News RSS feed for this section

For Rotavirus, Prevention is the Best Medicine

This commentary originally appeared in Global Health Now.

World Immunization Week provides a moment to reflect on the tremendous progress in reducing one of the world’s leading killers of children—diarrhea.

While oral rehydration solution has significantly reduced diarrheal disease mortality since its adoption in 1978, diarrhea continues to be a major cause of childhood illness and death globally. Rotavirus, the most common cause of severe diarrhea, is responsible for approximately 40% of all diarrhea hospitalizations and hundreds of thousands of deaths in children under 5.

Rotavirus vaccines offer the best protection for children and are an essential part of comprehensive diarrhea control. While the WHO recommends that all countries introduce rotavirus vaccines, only 77 have done so, 34 of which are Gavi-eligible countries where many of the deaths occur. Unfortunately, some of the most vulnerable children and communities do not have access to the vaccine.

In particular, Asia has lagged in introducing rotavirus vaccines, even though it accounts for more than 40% of global rotavirus deaths. To date, no country in the region has introduced the vaccine into its national immunization program.

While dramatic reductions in deaths from childhood diarrheal disease have been achieved in Bangladesh, there are still more than 2.4 million rotavirus cases each year. It causes 2 out of every 3 diarrhea-related hospitalizations among children under 5. There are also serious economic consequences. One episode of rotavirus costs the average Bangladeshi family about USD $80 in direct hospital costs, a significant portion of average monthly income.

In neighboring India, where rotavirus is equally ubiquitous, the disease poses a significant financial burden to families and the country’s economy. Studies have shown that a hospitalization for rotavirus could potentially push a family into poverty or keep them there. Depending on the level of care, the total cost of a rotavirus hospitalization could range anywhere from nearly $32 to more than $135, equal to up to 2 months of income for an average Indian family. Rotavirus also burdens the healthcare system with the high cost of hospitalizations and outpatient visits. One study estimated that hospitalizations and outpatient visits cost India approximately $78 million and $86 million each year, respectively—each more than the estimated $72 million it would cost to fund a rotavirus immunization program.

For fast-growing countries like India and Bangladesh, tackling rotavirus—which cheats children and the nation of productivity, well-being and development—should be a priority. However, the available and effective rotavirus vaccines are not yet available in the national immunization programs of either country.

Many of my scientific colleagues in Bangladesh are making a good case to their leaders for national introduction of rotavirus vaccines. And, I’m inspired by the strides being made in India. Last July, Prime Minister Narendra Modi announced that rotavirus will be included in the Universal Immunization Programme; and just last month, the first India-made rotavirus vaccine, ROTAVAC, was launched. Now is the time to get to the finish line—the cost of delaying access to rotavirus vaccines continues to mount. Together we can close this immunization gap and virtually eliminate rotavirus.

Dr. Mathuram Santosham is the Director of the Center for American Indian Health, Chair of the ROTA Council, and Senior Advisor at the International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health. Dr. Santosham and his colleagues won an Honorable Mention in GHN’s Untold Global Health Stories Contest for their submission of rotavirus in Bangladesh and India. GHN will feature one Honorable Mention story per month from now until the next contest in early 2016.

Roger Glass Awarded Prestigious Sabin Gold Medal for Vaccine Work

Credit: Sabin Vaccine Institute

ROTA Council member Dr. Roger I. Glass received the Albert B. Sabin Gold Medal Award at a ceremony on April 14, 2015, in Bethesda, Maryland. This award is presented annually to a distinguished member of the public health community who has made extraordinary contributions in the field of vaccinology or a complementary field.

Dr. Glass, currently director of the Fogarty International Center at the National Institutes of Health (NIH), is one of the world’s leading experts on gastroenteritis caused by rotavirus and norovirus. He has led global research on the introduction of rotavirus vaccines, adding to the body of knowledge showing rotavirus vaccines are safe, effective and the best way to prevent rotavirus diarrhea.

Dr. Glass is also one of the pioneers of ROTAVAC®, the indigenous Indian vaccine recently introduced into India’s private market and the product of an innovative public-private partnership between the NIH and Bharat Biotech, the U.S. Centers for Disease Control and Prevention and the Indian government, among others.

Other Council members to have received the Sabin Gold Medal include Dr. Mathuram Santosham and the late Dr. Ciro de Quadros.

Read more at the Sabin Vaccine Institute.

Bangladesh: Officials, Experts Agree on Urgent Need for Rotavirus Prevention

Experts gather in Dhaka on January 5, 2015.

The world’s foremost experts on rotavirus recently gathered in Dhaka, Bangladesh to discuss the country’s substantial disease burden, the expense associated with treatment and how to best support the introduction of rotavirus vaccines into the country’s national immunization program. Among the January 5 meeting attendees were government officials, immunization program officers and scientific experts.*

The latest research on rotavirus in Bangladesh indicates:

Rotavirus is a major problem

  • 2.4 million cases each year
  • Responsible for nearly two-thirds of all diarrhea-related hospitalizations in children under age 5 in 2013
  • Half of all rotavirus hospitalizations were among infants age 6-11 months

Rotavirus is expensive

  • Treatment in a hospital can cost a family US$84 per episode, in terms of both direct and indirect costs
  • Direct costs, such as medicine and diagnostic tests, amount to almost 20% of average monthly household income
  • US$66.8 million is the estimated total, annual nationwide cost for rotavirus hospitalizations

Prevention is possible

  • Vaccination against rotavirus can reduce the risk of infection by nearly half during the first year of life, when the threat is greatest
  • Rotavirus vaccines could prevent an estimated 135,000 hospitalizations per year
  • Rotavirus vaccines are safe and cost-effective

While progress has been made in reducing diarrhea-related deaths among children, it is still one of the leading causes of illness among children under 5 in Bangladesh. Rotavirus is a significant cause of these illness and hospitalizations. Rotavirus vaccines could have a powerful public health impact if introduced into Bangladesh’s national immunization program.

The ROTA Council applauds the government of Bangladesh for prioritizing this issue, and encourages officials to take steps toward introducing rotavirus vaccines, such as improving cold chain capacity and applying to Gavi, the Vaccine Alliance, for vaccine introduction support.

You can download a presentation delivered at this meeting by Dr. George Armah on Ghana as a case study here.

*The meeting was hosted by the Hospital Based Rotavirus and Intussusception Surveillance (HBRIS), Bangladesh and the ROTA Council. Attendees included representatives from:

  • Bangabandhu Memorial Hospital
  • Bangabandhu Sheikh Mujib Medical University
  • BRAC
  • Dhaka Medical College
  • Dhaka Shishu Hospital
  • Directorate General of Health Services
  • EPI, Government of Bangladesh
  • Institute of Epidemiology, Disease Control and Research
  • International Centre for Diarrhoeal Disease Research, Bangladesh
  • Jahurul Islam Medical College
  • Jalalabad Ragib-Rabeya Medical College
  • Jessore General Hospital
  • LAMB Hospital
  • Rajshahi Medical College Hospital
  • Sher-e-Bangla Medical College Hospital
  • U.S. Centers for Disease Control and Prevention
  • World Health Organization

Pneumonia and Diarrhea Progress Report 2014

A new report from the International Vaccine Access Center (IVAC) at Johns Hopkins University finds that despite major reductions in pneumonia and diarrhea deaths globally, progress has been slow in the highest-burden countries. The Pneumonia and Diarrhea Progress Report evaluates the progress made by the fifteen highest-burden countries in implementing high-impact interventions from the Global Action Plan on Pneumonia and Diarrhea (GAPPD), and highlights countries making strides toward reducing child mortality from pneumonia and diarrhea.

Read the full report here

Fresh onslaught against ravaging rotavirus disease

This article originally appeared in The Guardian (Nigeria).

The deadly Rotavirus has over the years ravaged Nigerian children unchecked. EMEKA ANUFORO of our Abuja Bureau writes on the cheery news that help is on the way as Nigeria finally announces plans to introduce a vaccine against the virus.

ROTAVIRUS diarrhea is considered a big threat to Nigerian children, and causes more than 160,000 deaths in children under five each year. A recent research indicates that the percentage of cases found in Enugu as the highest in Africa. Despite the availability of its vaccine worldwide, the deadly Rotavirus is still a leading cause of severe diarrhea disease and dehydration in infants and young children in Nigeria.

The World Health Organization (WHO) estimates that the rotavirus disease causes the death of approximately 527,000 young children yearly. About 85 per cent of these deaths are said to occur in developing countries, mainly in South Asia and sub-Saharan Africa.

Rotavirus, according to the United States Centre for Disease Control and Prevention (CDC), is a contagious virus that can cause inflammation of the stomach and intestines.

“Symptoms include severe watery diarrhea, often with vomiting, fever, and abdominal pain. Infants and young children are most likely to get rotavirus disease. They can become severely dehydrated and need to be hospitalized and can even die.”

Unfortunately, despite the deadly nature of the virus, Nigeria is yet to introduce a vaccine to contain the disease. The Guardian had reported that the country has not introduced a vaccine to curb the ailment.

But the good news is that come next year, the vaccine for Rotavirus would be available in Nigeria, if assurances by officials are anything to go by.

Executive Director of the National Primary Healthcare Development Agency (NPHCDA), Dr Ado Mohammed, whose agency has the mandate for vaccination, told The Guardian that the vaccine would be introduced next year (2015).

He said: “Diarrhea accounts for a major percentage of child mortality in Nigeria. We are working towards introducing rotavirus vaccine as part of other interventions that we are doing. You are aware that we have introduced flavored ORS in Nigeria, you are also aware that we have introduced sinc-surphate treatment regiment for diarrhea in Nigeria.

“We are working towards ensuring that we introduce rotavirus vaccine next year. By 2015, Rotavirus will come on board as part of our vaccine plans so that we can change lives and fast track our attainment of the MDGs goals 4 and 5 and ensure that we reduce to the barest minimum deaths attributable to the virus.”

A recent study indicates that the deadly Rotavirus is still ravaging Nigerian children unchecked.

Checks at the World Health Organization (WHO) indicate that vaccination against rotavirus diarrhea is one of the vaccinations recommended by the global body to be given to all children worldwide.

Rotavirus is seen as the primary cause of diarrhea-related illnesses and deaths, and according to experts, is responsible for 160,000 deaths in under -five (5) Nigerian children each year

A new study published in the Pediatric Infectious Disease Journal reveals that vaccines are available, but Nigeria is yet to introduce the vaccines.

An abstract on the publication stressed: “This study found a relatively high incidence of severe rotavirus-associated diarrhea disease in Nigeria and infants were the most affected. It highlights the urgent need for introduction of rotavirus vaccine into the national immunization program, the need to adequately equip health facilities, to enable them administer intravenous fluids to severe diarrhea patients to reduce morbidity and mortality.”

The researchers found in their study that rotavirus is responsible for close to 56 per cent of cases of diarrhea in children and that more case occur in the cool dry months of the year, a finding now regarded as one of the highest rates of diarrhea caused by rotavirus.

Reports indicate that vaccines are known to offer the best protection, and have indicate that vaccines are known to offer the best protection, and have been proven in study after study to be safe and effective in Africa and around the world.

But unfortunately, Rotavirus vaccines are not yet included in Nigeria’s immunization program.

“If Nigeria’s leaders take action, these lifesaving vaccines could be introduced as early as 2015. Every child is vulnerable, regardless of where they live, and for those in places without medical care it can be a death sentence,” the report noted.

A WHO factsheet on the virus indicate that: “Most symptomatic episodes occur in young children between the ages of 3 months and 2 years. The virus spreads rapidly, presumably through person-to-person contact, airborne droplets, or possibly contact with contaminated toys.

“Symptoms usually appear approximately two to three days after infection, and include projectile vomiting and very watery diarrhoea, often with fever and abdominal pain. The first infection is usually the worst one.

There is no specific drug treatment for rotavirus infection, although oral rehydration therapy is recommended. There are now two new rotavirus vaccines to prevent severe rotavirus disease.”

The study ‘Epidemiology of Rotavirus Diarrhea among Children Younger than 5 Years in Enugu, South East, Nigeria was recently conducted and the results published in Pediatric Infectious Disease Journal.

The Pediatric Infectious Disease Journal is an official publication of the European Society for Paediatric Infectious Diseases.

The Guardian learnt that researchers from the Nigerian Ministry of Health, Institute for Child Health and University of Nigeria Teaching Hospital, and World Health Organization recently examined the prevalence of rotavirus in hospitalized children under five (5).

The study was conducted in Enugu and found that the percentage of positive cases reported in Enugu was the highest level observed to date by the WHO Regional Office for Africa in Africa

Among other things, the report also found that more than half (56%) of children under 5 hospitalized with diarrhea were found to have rotavirus, while almost all (96%) of these children were under the age of two (2).

A copy of the report obtained by The Guardian describes January as the peak month for rotavirus infections. 95 per cent of rotavirus cases, it stressed, occurred between December and April,

The study particularly drew attention to the urgent need to protect Nigeria’s children from rotavirus.

The study noted:  “Severe rotavirus diarrhea in children is a major cause of morbidity globally and mortality in developing countries. It is estimated to be responsible for 453,000 deaths in children less than 5 years of age globally and 232,000 in the African region. The aim of the current study was to determine the prevalence of rotavirus gastroenteritis among hospitalized children less than 5 years of age in Enugu and to support awareness and advocacy efforts for the introduction of rotavirus vaccines in Nigeria…

“This study found a relatively high incidence of severe rotavirus-associated diarrhea disease in Nigeria and infants were the most affected. It highlights the urgent need for introduction of rotavirus vaccine into the national immunization program and the need to adequately equip health facilities so as  to enable them administer intravenous fluids to severe diarrhea patients to reduce morbidity and mortality.”

But President of the Nigerian Academy of Science, Prof Oyewale Tomori confirmed that the vaccines had not been introduced in Nigeria and called attention to the urgent need for the Nigerian government to introduce the vaccine into the nation’s vaccination program.

In an interview with The Guardian, he stressed how many of the countries that have introduced Rota vaccine no longer contend with polio, while measles is a minor problem such countries

According to him, “We need to accelerate the introduction of rotavirus vaccine in Nigeria. The vaccine is available for any nation who considers it important enough to give their children.”

On his thoughts on why government was yet o introduce the vaccine, Tomori, who is a virologist, stressed: “I think the government has done a fairly good job, but as we say ‘ water pass gari’.  The government has introduced new vaccines and plans to introduce more between now and 2015. The vaccines include Penta, Pneumococcal conjugate vaccine  (PCV), Human Papilloma Virus Vaccine, (HPV), Tetanus and fractional diphtheria (Td), measles-rubella vaccine (MRV) and rotavirus vaccine

“However, we could do more with the resources we have, if we spend our money wisely and judiciously. We hear of competing interests against vaccinating our children. I wish those competing interests were important things and issues. The things competing against providing our children with vaccines include: wastage, undue process, looting, stealing with conspicuous and obscene life style.”

On the likely implication of non-introduction of the vaccine on Nigerian children, he stressed; “Many of them will die from preventable diseases and we will not meet some of the Millennium Development Goals (MDG).”

He, nevertheless, gave kudos to the efforts of the Nigerian government in introducing vaccines for a number of child killer ailments, but noted:  “The government is trying, but we have too many disease conditions we should have controlled a long time ago.”

The Guardian reached out to a co-author of the study, Dr. George Armah, who noted that there had been several reports on the contribution of rotavirus to the large mortality in children which were in the possession of the Nigerian government.

Armah, Senior Research Fellow and Associate Professor at the University of Ghana, stressed that the introduction of rotavirus vaccines would help avert the risk of the more 41,000 kids dying from this vaccine preventable disease.

“It will reduce considerable the lost time for mothers who have to attend their sick children as well save the economy a lot of Naira from the treatment cost of the disease. “

He said the latest study aimed to determine the prevalence of rotavirus gastroenteritis among hospitalized children less than five years of age in Enugu.

“The data from this study was to augment support awareness and advocacy efforts for the introduction of rotavirus vaccines in Nigeria,” he noted.

He told The Guardian: “The main findings were that more than 50% of children admitted to the hospital with severe diarrhea infected with the human rotavirus. The majority of these unfortunate children (77%) were less than 12 months of age. These are very small and delicate children. The ones who made it to the hospital are the very lucky ones who will survive.

“For an unfortunate child in a hard to reach and inaccessible part of rural Nigeria – it is a death sentence and a lot of anxiety for the parents. The study showed that the incidence of disease, the months at which infection is at its peak (October to February) are very similar to countries in the sub-region and introduction of vaccines will help ameliorate the burden of disease as is being observed in countries that have introduced the vaccines in their Expanded Programme on Immunisation.

Global Buzz for Rotavirus Vaccines

This post originally appeared on Impatient Optimists.

By: Mathuram Santosham

Heading to New Delhi, India recently for the Eleventh International Rotavirus Symposium, I knew that this meeting would be different. Over the past couple of years, notable advancements against rotavirus disease have occurred, including the development of a new indigenously developed vaccine in India, an enormous mass of studies with positive safety and effectiveness results, and many introductions of vaccines into national immunization programs, giving promise that we can beat this leading killer of children.

In the very first moments of my arrival, I learned that my expectations were right.

Never before have more people gathered at this symposium. An astounding 650 experts from 56 countries — more than 16 times as many people who attended our first meeting thirty years ago — came to the conference, themed,“Building on evidence: the case for rotavirus immunization.”

The sheer number and diversity of people are true testaments to the increasing awareness of rotavirus and the essential role of vaccines in reducing the suffering this disease causes.

Pediatricians, epidemiologists, researchers, policy makers, immunization program implementers, government officials and pharmaceutical representatives presented on and heard about a number of important topics. Panels ranged from the Latin American and African experience with vaccines and post-licensure impact and safety of vaccination, to immunity and new insights in strain diversity.

In addition, we discussed the critical policy challenges remaining and advocacy efforts needed to help overcome them. Advocacy among policy-makers, championed by my dear colleague and friend, the late Dr. Ciro de Quadros, along with groundbreaking vaccine development efforts and public-private partnerships are leading to greater prioritization of rotavirus; however, more must be done.

But what also stood out was the excitement of convening this biannual event in India. The new government has made laudable commitments to tackling the burden of rotavirus, and other leading childhood diseases, that will save lives and give all Indian children a chance at being healthy and productive.

Just two months ago, Indian Prime Minister Narendra Modi announced that the Government of India would provide a rotavirus vaccine to all Indian children through the Universal Immunization Program. At the same time, the government has redoubled efforts to improve access to oral rehydration solution (ORS) and other key diarrhea control interventions through its Intensified Diarrhea Control Fortnight. All of these efforts are positive signs for the children of India.

At the symposium, Dr. Harsh Vardhan, India’s Union Minister of State for Health and Family Welfare, spoke about the importance of delivering vaccines to all those in need. Too many children have lost their lives, and too many families are bearing tremendous economic consequences as a result of hospitalizations due to rotavirus. In India, rotavirus is estimated to cause more than 78,000 deaths, 800,000 hospitalizations and three million outpatient visits each year.

However, even with this momentum, we must not become complacent in addressing rotavirus disease, the leading cause of severe and fatal diarrhea in children under five years of age worldwide, killing between a quarter and a half million children each year. While children everywhere are at risk of infection, the majority of deaths occur in South Asia and Sub-Saharan Africa, where children do not have good access to care.

Yet, despite the World Health Organization’s (WHO) recommendation for all countries to introduce rotavirus vaccines in their national immunization programs, only 35 percent of countries worldwide (69) have done so. The most disappointing statistic for me is that only one country in Asia — The Philippines — has introduced the vaccine nationally.

Additionally, while vaccination is the best way to protect children from rotavirus, a comprehensive approach will best protect child health and boost immunity. Vaccination should be part of a broad strategy that includes improved water, sanitation and hygiene; good nutrition; breastfeeding; ORS; and zinc supplementation.

I am hopeful that when we meet again for the next symposium, two years from now, we’ll have even more scientific and policy progress to celebrate and build on. Thanks to all of the dedicated rotavirus experts who participated and whose work is making a lasting difference in the health and well-being of children everywhere.

Thanks also to the conveners and funders: the Bill & Melinda Gates Foundation, U.S. Centers for Disease Control and Prevention, Christian Medical College Vellore, Indian Council of Medical Research, National Institutes of Health Fogarty International Center, PATH, ROTA Council, Sabin Vaccine Institute, Bharat Biotech, GlaxoSmithKline, Merck Pharmaceuticals, Serum Institute of India, Ltd. and WHO.

Learn more about how rotavirus vaccines can improve health and save lives at

Presentations Posted from Eleventh International Rotavirus Symposium

Presentations from the Eleventh International Rotavirus Symposium have been posted.

You can find them, as well as conclusions and findings from the meeting, on the Sabin Vaccine Institute’s website here.

Eleventh International Rotavirus Symposium Held in New Delhi, India

New Delhi, India — September 3, 2014 — The Eleventh International Rotavirus Symposium today began just two months after Indian Prime Minister Narendra Modi announced that the Government of India would provide a rotavirus vaccine to all Indian children, and weeks before the highly anticipated UN General Assembly’s 69th opening session, which will assess progress towards the Millennium Development Goals (MDGs).

At the three-day conference, more than 600 experts from 56 countries will examine new surveillance data and studies demonstrating the effectiveness and impact of vaccination for rotavirus, a leading cause of severe and fatal diarrhea in children under five years of age worldwide. Killing between a quarter and a half a million children each year, rotavirus significantly impedes achieving MDG4: reduce child mortality.

“We cannot reduce death and suffering from rotavirus — as well as its significant economic toll —without vaccines,” said Dr. Mathuram Santosham, chair of ROTA Council and professor of International Health and Pediatrics at Johns Hopkins University in Baltimore, Maryland, United States. “Greater prioritization of rotavirus vaccines will protect children and avoid substantial health costs to families and healthcare systems. India, which has a heavy rotavirus burden but is home to a promising new vaccine, is the perfect setting to evaluate the current scientific evidence on rotavirus vaccines to inform decision-making.”

Globally, diarrhea is one of the most common causes of hospitalizations of children. According to the World Health Organization (WHO), more than one-third (36 percent) of all hospitalizations for severe diarrhea are caused by rotavirus. In some settings around the world, hospitalizations are a tremendous financial burden to already impoverished families and strain health systems. However, rotavirus vaccines could cut hospitalizations of children under five by four to eight percent and substantially improve child health and survival.

If used in all GAVI-eligible countries, rotavirus vaccines could also prevent an estimated 180,000 deaths and avert six million clinic and hospital visits each year, saving US $68 million in annual treatment costs. Yet, despite the WHO’s recommendation for all countries to introduce rotavirus vaccines in their national immunization programs, only 35 percent of countries worldwide (69) have done so. Of those countries, only one is in Asia.

This summer, India announced it would introduce a new vaccine, shown to reduce severe diarrhea caused by rotavirus by 56 percent during the first year of life. Rotavirus is estimated to cause more than 78,000 deaths, 800,000 hospitalizations and three million outpatient visits each year in India.

“Every child deserves the chance to live a long, healthy, productive life,” said Dr. Gagandeep Kang, head of the Wellcome Trust Research Laboratory at the Christian Medical College in Vellore, Tamil Nadu, India. “When rotavirus vaccines are part of a comprehensive strategy including oral rehydration solution (ORS), breastfeeding, good nutrition, and improved water, sanitation and hygiene, we can make this vision a reality.”

Overall, 95 percent of rotavirus deaths occur in developing countries in Asia and Africa. In Asia, rotavirus kills approximately 188,000 children under five each year and in Africa, rotavirus kills 232,000 children under five each year. However, children everywhere are at risk of infection.

The Eleventh International Rotavirus Symposium brings together scientists, clinicians, public health professionals, immunization leaders, vaccine industry representatives and members of the donor community. The Sabin Vaccine Institute serves as the organizing secretariat. The full list of conveners can be found at, and the agenda can be found here.

ROTA Council Convenes Leading Experts on Rotavirus Vaccines for Scientific Workshop


On July 23 and 24, the ROTA Council, along with its core partners the International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health, PATH, the Sabin Vaccine Institute and the U.S. Centers for Disease Control and Prevention, gathered a group of rotavirus technical experts and public health officials, leading research and advocacy organizations, funders and vaccine manufacturers for “The Rotavirus Vaccination & Intussusception Workshop: Science, Surveillance & Safety.”

The event, held in Washington, DC, and funded by the Bill & Melinda Gates Foundation, was an important step in helping the global health community understand the benefits and risks of rotavirus vaccines, which offer the best protection against rotavirus and the deadly diarrhea that it causes.

Intussusception is a bowel blockage, which in extremely rare cases is associated with rotavirus vaccines. For every 100,000 children vaccinated, there are an estimated 1-6 extra cases of intussusception. However, numerous studies have demonstrated that the benefits of the vaccine outweigh the risk. Despite this, the lack of understanding about the benefits and risks of rotavirus vaccines can delay introduction of these live-saving vaccines, causing hundreds of thousands of preventable deaths and hospitalizations among young children.

At the workshop, the technical experts in attendance reviewed and evaluated the current evidence on intussusception and rotavirus vaccines, identified and prioritized remaining gaps in the research, discussed challenges and opportunities around new vaccines coming to market or currently in clinical trials, and documented the scientific consensus on best practices for monitoring and communicating the potential risk of intussusception after the introduction of rotavirus vaccines. The meeting outcomes will be published in a peer-reviewed journal and provide a current, reliable source of the latest evidence and scientific consensus on rotavirus vaccine safety and intussusception.

ROTA Council Remembers Ciro de Quadros

“The ROTA Council joins the global health community in celebrating the life of Dr. Ciro de Quadros, a public health hero and our Council co-chair, who passed away peacefully yesterday in his home, surrounded by family. Ciro’s contributions to the field of vaccines are immeasurable, and his legacy will live on in the millions of children’s lives saved each year by vaccines. On a personal note, his boundless energy, sense of humor, and passion were infectious and will be greatly missed.” – Dr. Mathu Santosham, Co-Chair, ROTA Council 

To read additional news of Ciro’s passing, visit the Sabin Vaccine Institute website: